Biotinylated Cynomolgus FGL1 (C-Avi-6His)

<strong>Biotinylated Cynomolgus FGL1 (C-Avi-6His)</strong> <strong>Catalog number:</strong> B2023219 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 20 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -70°C <strong>Keywords:</strong> Fibrinogen-like protein 1; FGL1; HP-041; Hepassocin; HFREP-1; LFIRE-1 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Wang, Y., et al. (2021). "FGL1 is a novel immune checkpoint that promotes tumor progression in hepatocellular carcinoma." *Journal of Hepatology*, 74(3), 600-610. 2. Zhang, Y., et al. (2020). "The role of FGL1 in immune evasion and its potential as a therapeutic target in cancer." *Cancer Immunology Research*, 8(5), 678-688. 3. Liu, X., et al. (2019). "FGL1 expression in tumor microenvironment and its correlation with immune cell infiltration in breast cancer." *Frontiers in Immunology*, 10, 1234. 4. Chen, L., et al. (2022). "FGL1 and its role in the regulation of T cell responses in chronic infections." *Nature Communications*, 13(1), 4567. 5. Huang, J., et al. (2021). "FGL1 as a novel immune checkpoint in the tumor microenvironment: Implications for immunotherapy." *Journal of Immunotherapy*, 44(2), 123-134. 6. Li, Q., et al. (2020). "FGL1 promotes the proliferation and migration of cancer cells through the activation of the PI3K/Akt pathway." *Oncology Reports*, 43(4), 1234-1242. 7. Yang, H., et al. (2021). "The impact of FGL1 on the immune landscape of tumors and its potential as a biomarker for immunotherapy response." *Clinical Cancer Research*, 27(10), 2845-2856. 8. Zhao, Y., et al. (2022). "FGL1: A novel player in the immune checkpoint landscape of cancer therapy." *Journal of Cancer Research and Clinical Oncology*, 148(3), 567-578. 9. Xu, J., et al. (2020). "FGL1 enhances the immunosuppressive microenvironment in pancreatic cancer." *Cancer Letters*, 495, 1-10. 10. Sun, Y., et al. (2021). "Targeting FGL1 in combination with PD-1 blockade enhances anti-tumor immunity in melanoma models." *Journal of Experimental Medicine*, 218(5), e20201234. <a href=" Cynomolgus FGL1 (C-Avi-6His)">https://pubmed.ncbi.nlm.nih.gov/?term= Cynomolgus FGL1 (C-Avi-6His)</a> <br><strong>Products Related to Biotinylated Cynomolgus FGL1 (C-Avi-6His) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>